RAPID MICRO BIOSYSTEMS, INC. RPID
Nasdaq · XNAS · stock · Laboratory Analytical Instruments
Chart by TradingView
2/9
Piotroski F — financial health
-22.43
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $33.6M | -$47.1M | — | -$31.9M | $33.2M |
| 2024 | $28.1M | -$46.9M | — | -$45.5M | $75.4M |
| 2023 | $22.5M | -$52.5M | — | -$46.9M | $118.0M |
| 2022 | $17.1M | -$60.8M | — | -$65.3M | $164.2M |
| 2021 | $23.2M | -$73.5M | — | -$58.2M | $221.0M |
| 2020 | $16.1M | -$37.1M | — | -$31.7M | -$127.0M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -22.43 (distress)
- Working capital / assets 0.57
- Retained earnings / assets -6.979
- EBIT / assets -0.633
- Equity / liabilities 0.797
Source: SEC EDGAR filings · CIK 0001380106 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.